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Abstract. Background: n-3 fatty acids are increasingly being
administered to cancer patients for the treatment of cachexia,
and it is thus important to know of any potential interactions
with ongoing cytotoxic drug therapy. Materials and Methods: For
this reason eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) were administered to mice bearing the cachexia-
inducing MAC16 colon adenocarcinoma, and the effect of
epothilone, gemcitabine, 5-fluorouracil and cyclophosphamide
on tumour growth and body weight determined. Results:
Epothilone alone had a minimal effect on tumour growth rate,
but this was potentiated by DHA, while for 5-fluorouracil and
cyclophosphamide tumour growth inhibition was enhanced by
EPA. The antitumour effect of gemcitabine was not altered by
either fatty acid. EPA arrested the development of cachexia,
while DHA had no effect and the same was true for their effect
on tumour growth rate. The anticachectic effect of EPA was
only seen in combination with 5-fluorouracil. Conclusion: These
results suggest that n-3 fatty acids do not interfere with the action
of chemotherapy and may potentiate the effect of certain agents.
Polyunsaturated fatty acids (PUFA) of the n-3 series,
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), have important roles in inhibiting tumour growth
and metastasis (1). EPA has been shown to attenuate the
development of weight loss in patients with advanced
pancreatic cancer (2), and a fish oil enriched nutritional
supplement, high in protein and energy, has been shown to
promote weight gain in cachectic cancer patients through an
increase in lean body mass (3). In addition, n-3 PUFA have
a considerable immunomodulating effect in patients with
solid tumours, increasing the ratio of T-helper cells to T-
suppressor cells, prolonging the survival of both cachectic
and non-cachectic subjects (4).
Incorporation of n-3 PUFAs into membrane lipids would
alter membrane fluidity and membrane-related functions
and could influence the uptake of cytotoxic chemicals.
Modification of tumour cell membranes with DHA has been
shown to significantly enhance the sensitivity of L1210
murine leukaemic cells to the antineoplastic agent
adriamycin (5), as well as chemoresistant human small cell
lung cancer cell lines, concomitant with a 10-30% increase
in adriamycin concentration (6). Fish oil has also been
shown to enhance the antitumour effect of optimal doses of
doxorubicin, as well as reducing severe heart damage caused
by high doses of this agent (7), and DHA has been shown
to increase the sensitivity of a human small cell carcinoma
cell line to cisplatin (8).
Fish oil supplements are now marketed in high-energy
and high-protein, calorically dense nutritional supplements
as Resource® Support and ProSure for the treatment of
cancer patients. It is thus important to understand how these
n-3 PUFAs interact with chemotherapy. This study examines
the effect of EPA and DHA alone and in combination with
selected chemotherapeutic agents on tumour growth and
cachexia using the MAC16 murine cachexia model (9). The
MAC16, like most human tumours producing cachexia, is
highly chemoresistant (10) and is thus considered a good
model to study chemotherapeutic interactions.
Materials and Methods
Materials. EPA and DHA were obtained as their triglycerides
Omegavie 90-TG from Polaris, France and contained 93.2% EPA
and 93.5% DHA, respectively. Epothilone (EP0906) was a gift
from Novartis Pharmaceuticals, Switzerland, and all other materials
were purchased from Sigma Aldridge, Dorset, UK.
Animals. Pure strain male NMRI mice were bred in our own colony
and were transplanted with fragments (1-2mm3) of the MAC16
tumour s.c. into the flank, by means of a trochar, as described (9).
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All animal experiments followed a strict protocol, approved by the
British Home Office. Transplanted animals were given free access
to food and water and experiments were initiated when the tumour
became palpable, at which time the average weight loss was about
5%. The fatty acids were administered as triglycerides in olive oil.
The concentrations of EPA and DHA were based on those
previously reported to exert an anticachectic and antitumour effect
as the free acid (11). Control animals received olive oil alone. The
solvents for the chemotherapeutic agents and the dose regime is
indicated in the figure legends. Body weight was measured daily by
means of a top loading balance, and tumour dimensions were
measured by means of calipers. Tumour volume (T.V.) was
calculated from the formula:
length x (width)2
T.V. =
2
Animals were terminated if the tumour volume exceeded 1000mm3,
the tumour ulcerated, or if weight loss exceeded 25% of the
starting body weight. All experiments have been carried out with
groups of 10 mice (6-8 weeks of age, average weight 25g).
Statistical analysis. Results are expressed as means±s.e.m.
Differences were determined by one-way ANOVA followed by
Tukey-Kramer Multiple Comparison Test.
Results
Effects of fatty acids alone. Treatment of mice bearing the
MAC16 tumour with EPA alone (2g/kg) produced a small
but significant inhibition of tumour growth rate (Figure 1A),
while producing almost complete attenuation of the
development of cachexia (Figure 1B). This shows that EPA
as the triglyceride was as effective as the free acid (11). This
contrasts with the ethyl ester, which has been shown to be
devoid of antitumour and anticachectic activity (12). In
contrast to EPA, DHA (2.25g/kg) had no significant effect
on either the growth of the MAC16 tumour (Figure 1A) or
on the development of weight loss (Figure 1B).
Effect of combination with epothilone. The epothilones are a
new group of microtubule-stabilizing compounds, derived
from the fermentation of the myxobacterium Sorangium
cellulosum, which possess potent in vivo antitumour activity
in some experimental animal models (13). The effect of
epothilone alone or combined with either EPA or DHA on
tumour growth and weight loss in mice bearing the MAC16
tumour is shown in Figure 2. Epothilone alone (2.5 mg/kg)
had a minimal effect on tumour growth rate, which was not
significant (Figure 2A). There was a significant reduction in
tumour growth rate when epothilone was combined with
DHA, but not EPA, nor the combination of EPA and DHA
(Figure 2A). There was no increase in weight loss in mice
treated with epothilone (Figure 2B), but epothilone
appeared to attenuate the anticachectic effect of EPA.
Effect of combination with gemcitabine. Gemcitabine (2’, 2’-
difluro-2’-deoxycytidine) is a fluorine-substituted cytarabine
analogue, which is the agent of choice in the palliative
treatment of pancreatic cancer (14). Gemcitabine alone
(50mg/kg) had no significant effect on the growth of the
MAC16 tumour (Figure 3A), and this did not appear to be
enhanced or reduced by combination with either EPA or
DHA. Gemcitabine had no effect on the development of
cachexia in the MAC16 model (Figure 3B), and the
anticachectic effect of EPA alone (Figure 1B) was not seen
in combination with gemcitabine (Figure 3B).
Effect of combination with 5-fluorouracil (5-FU). 5-FU is an
antimetabolite used to treat a number of solid tumours,
including colon and breast cancer. 5-FU alone (80 mg/kg)
inhibited growth of the MAC16 tumour and the
combination with EPA or DHA gave a further small
increase in tumour growth inhibition (Figure 4A). 5-FU did
not produce a significant decrease in the loss of body weight
(Figure 4B), but the combination with EPA was highly
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Figure 1. Effect of the synthetic triglycerides of EPA (2g/kg;■) and DHA (2.25g/kg; ▲) administered p.o. daily in olive oil, compared with olive oil
alone (◆) on tumour growth rate (A) and body weight loss (B) in mice bearing the MAC16 tumour. Differences from control are indicated as a, p<0.05,
b, p<0.01 and c, p<0.001.
effective in preventing the development of cachexia
compared with 5-FU alone.
Effect of combination with cyclophosphamide. Cyclo-
phosphamide is an alkylating agent, which requires metabolic
activation in the liver to produce the active species, and is
widely used in the treatment of chronic leukaemia, the
lymphomas and solid tumours. Cyclophosphamide (300
mg/kg) alone produced a small non-significant inhibition of
tumour growth, and this was significantly potentiated by EPA,
but not DHA (Figure 5A). EPA had a minimal effect on the
weight loss profile in mice receiving cyclophosphamide
(Figure 5B).
Discussion
Combinations of antitumour agents have proved more
efficacious in the treatment of human cancer than single agent
Wynter et al: Effect of w-3 Fatty Acids on Antitumour Activity
545
Figure 2. Effect of epothilone (2.5mg/kg in 10% DMSO + PBS) administered i.p. as a single dose on day 2, alone (■), or combined with EPA (2g/kg;
■), DHA (2g/kg; X) or EPA and DHA (▲) on tumour growth rate (A) and body weight loss (B) in mice bearing the MAC16 tumour. The fatty acids
were administered p.o. daily in olive oil and control animals (◆) received olive oil alone. Differences from control are shown as a, p<0.05. Treatment
with EPA and DHA alone is shown in Figure 1.
Figure 3. Effect of gemcitabine (50mg/kg in PBS) administered i.p. on alternate days, alone (■) or combined with EPA (2g/kg; ■), DHA (2g/kg; X) or
EPA and DHA (▲) on tumour growth rate (A) and body weight loss (B) in mice bearing the MAC16 tumour. The fatty acids were administered p.o. daily
in olive oil and control animals received olive oil alone (◆). There was no difference in any parameter from control animals administered PBS.
Differences from control are indicated as a, p<0.05. Treatment with EPA and DHA alone is shown in Figure 1.
treatment alone. Treatments tend to be additive if the locus
for tumour inhibition is different for each agent in the
combination. Since fish oil preparations rich in EPA and
DHA are increasingly being used in the treatment of cancer
cachexia (3), it is important to look for any interactions with
commonly used antineoplastic drugs, that may be either
synergistic or antagonistic. Tumour growth inhibition by EPA
has been shown to be effectively reversed by treatment with
the n-6 PUFA linoleic acid (15), suggesting the involvement
of prostaglandin or lipoxygenase metabolites in its antitumour
action. However, the anticachectic effect of EPA was not
reversed by linoleic acid, suggesting that the two effects were
separate (15), and the results with the chemotherapeutic
agents show that inhibition of tumour growth does not
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Figure 4. Effect of 5-FU (80mg/kg in PBS) administered i.p. on alternate days alone (■), or combined with EPA (2g/kg; ■), DHA (2g/kg; X) or EPA
and DHA (▲) on tumour growth rate (A) and body weight loss (B) in mice bearing the MAC16 tumour. The fatty acids were administered p.o. daily in
olive oil and control animals (◆) received either olive oil or PBS. Differences from control are indicated as a, p<0.05, b, p<0.01 or c, p<0.001.
Treatment with EPA and DHA alone is shown in Figure 1.
Figure 5. Effect of cyclophosphamide (300mg/kg in PBS) administered i.p. as a single dose on day 1 (■), or combined with EPA (2g/kg; ■), DHA
(2g/kg; X) or EPA and DHA (▲) on tumour growth rate (A) and body weight loss (B) in mice bearing the MAC16 tumour. The fatty acids were
administered p.o. daily in olive oil and control animals (◆) received either olive oil or PBS. Differences from control are indicated as a, p<0.05.
Treatment with EPA and DHA alone is shown in Figure 1.
substantially effect the rate of weight loss. DHA appears to be
devoid of antitumour activity in the MAC16 model, suggesting
that the two PUFAs act by different mechanisms, as also
observed in their ability to prevent weight loss, where EPA
exerts a profound anticachectic effect, while DHA is devoid
of anticachectic activity (16).
The MAC16 tumour model is highly chemoresistant (10)
and most of the agents used had minimal antitumour
activity, thus allowing analysis of any synergistic
combinations. For gemcitabine, neither PUFA had any
additional effect on tumour growth inhibition. However, for
epothilone tumour growth inhibition was increased when in
combination with DHA and for 5-FU and cyclophosphamide
tumour growth inhibition was enhanced in combination with
EPA, while the antitumour effect of gemcitabine was not
altered by either PUFA. Of the four agents studied, the
anticachectic effect of EPA was only seen in combination
with 5-FU, suggesting that anticachectic treatment with EPA
combinations may be more effective if administered between
the cycles of chemotherapy. This might be expected, since
EPA would not be expected to counter any weight loss due
to drug toxicity. The results suggest that innate drug
resistance is not overcome by an alteration of the lipid
domain of the cell membrane, but nevertheless the
antitumour efficacy of certain agents may be enhanced by
concomitant administration of a fish oil preparation rich in
EPA and DHA, while these PUFAs do not interfere with the
antitumour effectiveness of other agents, suggesting that a
fish oil- containing supplement can be taken during
chemotherapy.
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